An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

Overview of attention for article published in Frontiers in immunology, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 7 X posts from 6 X users, with an upper bound of 88,800 followers.

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response https://t.co/WfTvNFa6kS https://t.co/86Pr5Et4GT

19 Nov 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune respo…

17 Nov 2022

Reply Repost Favourite

Despite the limitation of this study is the small number of animals in the immune response analysis, results suggest that recombinant RBD-Fc delivered via intranasal vaccination has considerable potential as a mucosal vaccine that may reduce the risk of SA

17 Nov 2022

Reply Repost Favourite

Chen L, Zhang H, Li M, Wu B, Zhang Z and Gong R (2022) An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Front. Immunol. 13:1005321. doi: 10.3389/fimmu.2022.1005321 https://t.co/JiW4PivamL https

17 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.